# Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance), Division: Laboratory Criteria

Extent: E+W+S+N.I.

At least one of the following:
Demonstration of Treponema pallidum in lesion exudates or tissues by dark-field microscopic examination
Demonstration of Treponema pallidum in lesion exudates or tissues by DFA test
Demonstration of Treponema in lesion exudates or tissues by nuclear acid amplification techniques (NAAT)
Detection of Treponema pallidum antibodies by screening test (TPHA, TPPA or EIA) AND additionally detection of either TP-IgM antibodies (for example, IgM-ELISA or immunoblot or 19S-IgM-FTA-abs) OR non-TP antibodies (for example, RPR, VDRL).

---
Source: https://www.legislation.gov.uk/eudn/2018/945/annex/II/division/3/division/3.43/division/2 (the official version)
Page: https://openlegislation.uk/eu-decision-2018-945/annex-II/division-3/division-3.43/division-2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.